Pharvaris NV (PHVS)
38.17
+0.43
(+1.14%)
USD |
NASDAQ |
Sep 10, 12:51
Pharvaris Shareholders Equity (Quarterly) : 343.92M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 343.92M |
| March 31, 2026 | 272.30M |
| December 31, 2025 | 318.60M |
| September 30, 2025 | 366.88M |
| June 30, 2025 | 216.38M |
| March 31, 2025 | 243.41M |
| December 31, 2024 | 277.27M |
| September 30, 2024 | 331.23M |
| June 30, 2024 | 356.64M |
| March 31, 2024 | 387.90M |
| December 31, 2023 | 424.24M |
| September 30, 2023 | 162.12M |
| June 30, 2023 | 189.54M |
| March 31, 2023 | 140.31M |
| Date | Value |
|---|---|
| December 31, 2022 | 159.30M |
| September 30, 2022 | 181.40M |
| June 30, 2022 | 199.24M |
| March 31, 2022 | 212.39M |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 117.20M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 20.96M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Novartis AG | 41.54B |
| BioAge Labs, Inc. | 374.91M |
| AstraZeneca PLC | 47.33B |
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 375.77M |
| Total Liabilities (Quarterly) | 31.85M |
| Debt to Equity Ratio | 0.0022 |
| Current Ratio | 11.94 |
| Net Debt Paydown Yield | 0.00% |